SCHEMBL23080341

SCHEMBL23080341

CC(C)C1CCCC2(CCN(C(C)CC3CCC4(CCN(C(C)C)C4)CN3C(C)C)C2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19755633 0.83 HRH3 (0.32)
SCHEMBL21075797 0.83 HRH3 (0.32)
SCHEMBL19755636 0.77 HRH3 (0.32)
SCHEMBL17827391 0.77 HRH3 (0.31)
SCHEMBL19755634 0.74 HRH3 (0.32)
SCHEMBL19755637 0.74 HRH3 (0.34)
SCHEMBL19353348 0.72
SCHEMBL24817964 0.72 HRH3 (0.33)
SCHEMBL14524119 0.72 HRH3 (0.33)
SCHEMBL24840554 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186578-B2 Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors SHENZHEN TARGETRX, INC. (CN) 2021-11-30 US disclosed
US-20210070758-A1 FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE Shenzhen TargetRx. Inc. (CN) 2021-03-11 US disclosed